Tirabrutinib hydrochloride NEW
| Price | $30 | $43 | $71 |
| Package | 2mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Tirabrutinib hydrochloride | CAS No.: 1439901-97-9 |
| Purity: 99.27% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Tirabrutinib hydrochloride |
| Description | Tirabrutinib hydrochloride is a potent, highly selective, and irreversible oral BTK inhibitor. Tirabrutinib hydrochloride irreversibly covalently binds to Bruton tyrosine kinase (BTK) in B cells and exhibits potent in vitro cytotoxicity against many types of B cell malignancies, as well as in vivo antitumor activity in mouse models [1]. |
| In vitro | METHODS: Tirabrutinib hydrochloride (0.1-1000 nM or 0.001-100 nM; 72 h) was used to treat DLBCL cell lines SU-DHL-6 and OCI-LY10 to observe the anti-tumor effect on cells. RESULTS The IC50 values of Tirabrutinib hydrochloride against SU-DHL-6 and OCI-LY10 cell lines were 9.127 μM, and 17.10 μM.[1] |
| In vivo | Parental TMD8 mice were treated with tirabrutinib (6, 20 mg/kg; p.o.) to confirm whether tirabrutinib remains active in vivo. RESULTS 0.012% of tirabrutinib resulted in tumor remission in mice. [2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 95 mg/mL (193.51 mM), Sonication is recommended. |
| Keywords | B cells | ONO 4059 | haematological malignancies | Bruton tyrosine kinase | PCNSL | Tirabrutinib | GS-4059 | Inhibitor | ONO-4059 | Tirabrutinib Hydrochloride | ONO4059 | GS4059 | autoimmune disorders | Tirabrutinib hydrochloride | Apoptosis | Btk | inhibit | GS 4059 |
| Inhibitors Related | evobrutinib | (±)-Zanubrutinib | CP-547632 | BMS-986142 | Edralbrutinib | Sunvozertinib | Ibrutinib | IBT6A | Orelabrutinib | Atuzabrutinib | Remibrutinib | CGI-1746 |
| Related Compound Libraries | Highly Selective Inhibitor Library | Bioactive Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Kinase Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $30.00/2mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $9.00/1KG |
Hong Kong Tiansheng New Material Trading Co., Ltd
|
2021-11-26 | ||
| $9.00/1KG |
Hong Kong Tiansheng New Material Trading Co., Ltd
|
2021-11-26 | ||
| $9.00/1KG |
Hong Kong Tiansheng New Material Trading Co., Ltd
|
2021-09-24 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hills
INQUIRY